ACCU-CHEK® Blood Glucose Meters by Roche Rank Highest in Overall Satisfaction for the Second Consecutive Year According to J.D. Power Study

In an unprecedented, challenging environment for reimbursement and choice for people with diabetes, ACCU-CHEK remains highest ranked brand

News provided by

Roche

Feb 12, 2014, 11:15 ET

INDIANAPOLIS, Feb. 12, 2014 /PRNewswire/ -- J.D. Power has announced that Roche Diabetes Care's ACCU-CHEK products rank "Highest in Customer Satisfaction with Blood Glucose Meters" among adults living with diabetes in the U.S. for the second year in a row according to the 2013 Blood Glucose Meter Satisfaction Study^SM. In a study comprised of 2,123 participants, ACCU-CHEK meters ranked highest among competitors in respondents' assessments of key blood glucose meter characteristics, including meter performance, features and test strip cost.

"Blood glucose meters help people living with diabetes make important, daily decisions about their self-care," said Debbie Hinnen, a diabetes educator and the director of education services at Mid-America Diabetes Association. "It is important that people with diabetes talk with a healthcare provider about the importance of using a quality meter that will best suit their health needs and consistently provide accurate readings."

Roche, the maker of ACCU-CHEK products, has been a leading provider of blood glucose monitoring systems for nearly 40 years. The ACCU-CHEK product portfolio includes multiple meter and test strip combinations to accommodate the individual lifestyle and medical needs of Americans managing diabetes over the long term. This includes the ACCU-CHEK Nano SmartView and ACCU-CHEK Aviva Plus systems. These products provide users with consistently accurate readings. Individuals with diabetes trust their meters to help them make critical health choices every day, such as determining how much insulin to administer, modifying carbohydrate intake and adjusting activity levels.

"Roche is pleased that ACCU-CHEK products have retained this prestigious ranking," said Marc Gibeley, head of Roche Diabetes Care North America. "This ranking represents our ongoing commitment to provide blood glucose meters that help improve the lives of people living with diabetes."

ACCU-CHEK Nano and ACCU-CHEK Aviva meters and their test strips are manufactured in the U.S. and are broadly available to all patients through pharmacies and mail-order providers. For more information about ACCU-CHEK products, visit www.accu-chek.com.

About the Study:
Roche Diagnostics received the highest numerical score in the proprietary J.D. Power 2012-2013 Blood Glucose Meter Satisfaction Studies^SM. The 2013 study was based on 2,123 total responses measuring four providers and measured the opinions of consumers who use a blood glucose meter. Proprietary study results are based on experiences and perceptions of consumers surveyed September 2013. Your experiences may vary. Visit www.jdpower.com.

About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, insulin infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Camille Scott
(212) 593 6335
[email protected]

SOURCE Roche